首页 > 最新文献

Journal of Cancer Policy最新文献

英文 中文
Social media engagement of supportive care publications in oncology 肿瘤学辅助护理出版物的社交媒体参与。
IF 1.3 Q3 Medicine Pub Date : 2024-06-07 DOI: 10.1016/j.jcpo.2024.100491
Sruthi Ranganathan , David J. Benjamin , Alyson Haslam , Vinay Prasad

Importance

There is an increasing number of cancer ‘survivors’ and increasing research into supportive care. However, it is unknown how patterns of attention and citation differ between supportive and non-supportive cancer care research. We sought to estimate the engagement of high-impact studies of supportive compared to non-supportive cancer care papers.

Methods

In a cross-sectional review of top oncology journals (2016–2023), we reviewed studies examining supportive care strategies and a frequency-matched random sampling of studies on non-supportive interventions. We compared data on social engagement metrics, as represented by Altmetric scores and citations and funding status, by supportive care or non-supportive care articles.

Results

We found overall Altmetric scores were no different between articles that did not test supportive care and those that did, with a numerically higher score for supportive care articles (86.0 vs 102; p=0.416). Other bibliometric statistics (such as the number of blogs, number of X users, and the number of X posts) obtained from Altmetric did not differ significantly between the two groups. Non-supportive cancer care papers had a significantly higher number of citations than supportive cancer care papers (45.6 in supportive care vs 141 in non-supportive care papers; p<0.001). A greater proportion of non-supportive cancer care papers were also supported by pharmaceutical companies compared to supportive cancer care papers (54.2 % vs 15.3 %; p<0.001).

Conclusion

Though social media engagement is similar between supportive and non-supportive cancer care papers in high-impact journals, there is a significant difference in support from pharmaceutical companies and the number of citations.

重要性:癌症 "幸存者 "越来越多,对支持性护理的研究也越来越多。然而,人们还不知道支持性和非支持性癌症护理研究的关注和引用模式有何不同。我们试图估算支持性癌症护理研究与非支持性癌症护理研究论文的参与度:在对顶级肿瘤学期刊(2016-2023 年)的横向回顾中,我们回顾了有关支持性护理策略的研究,并对有关非支持性干预措施的研究进行了频率匹配的随机抽样。我们比较了支持性护理或非支持性护理文章的社会参与指标数据,这些指标由 Altmetric 分数和引用及资助状况表示:我们发现,未进行支持性护理测试的文章与进行了支持性护理测试的文章在 Altmetric 总分上没有差异,但支持性护理文章的得分更高(86.0 vs 102;P=0.416)。从 Altmetric 获得的其他文献计量统计数据(如博客数量、X 用户数量和 X 帖子数量)在两组之间没有显著差异。非支持性癌症护理论文的引用次数明显高于支持性癌症护理论文(支持性护理论文为45.6次,非支持性护理论文为141次;p结论:虽然在高影响力期刊中,支持性和非支持性癌症护理论文的社交媒体参与度相似,但在来自制药公司的支持和被引用次数方面存在显著差异。
{"title":"Social media engagement of supportive care publications in oncology","authors":"Sruthi Ranganathan ,&nbsp;David J. Benjamin ,&nbsp;Alyson Haslam ,&nbsp;Vinay Prasad","doi":"10.1016/j.jcpo.2024.100491","DOIUrl":"10.1016/j.jcpo.2024.100491","url":null,"abstract":"<div><h3>Importance</h3><p>There is an increasing number of cancer ‘survivors’ and increasing research into supportive care. However, it is unknown how patterns of attention and citation differ between supportive and non-supportive cancer care research. We sought to estimate the engagement of high-impact studies of supportive compared to non-supportive cancer care papers.</p></div><div><h3>Methods</h3><p>In a cross-sectional review of top oncology journals (2016–2023), we reviewed studies examining supportive care strategies and a frequency-matched random sampling of studies on non-supportive interventions. We compared data on social engagement metrics, as represented by Altmetric scores and citations and funding status, by supportive care or non-supportive care articles.</p></div><div><h3>Results</h3><p>We found overall Altmetric scores were no different between articles that did not test supportive care and those that did, with a numerically higher score for supportive care articles (86.0 vs 102; p=0.416). Other bibliometric statistics (such as the number of blogs, number of X users, and the number of X posts) obtained from Altmetric did not differ significantly between the two groups. Non-supportive cancer care papers had a significantly higher number of citations than supportive cancer care papers (45.6 in supportive care vs 141 in non-supportive care papers; p&lt;0.001). A greater proportion of non-supportive cancer care papers were also supported by pharmaceutical companies compared to supportive cancer care papers (54.2 % vs 15.3 %; p&lt;0.001).</p></div><div><h3>Conclusion</h3><p>Though social media engagement is similar between supportive and non-supportive cancer care papers in high-impact journals, there is a significant difference in support from pharmaceutical companies and the number of citations.</p></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2024-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141296858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A review of factors influencing the uptake of prostate cancer treatment in Nigeria 尼日利亚前列腺癌治疗的影响因素综述。
IF 1.3 Q3 Medicine Pub Date : 2024-06-06 DOI: 10.1016/j.jcpo.2024.100487
Chinonyerem O. Iheanacho , Valentine U. Odili

Background

The uptake of prostate cancer (PCa) treatment determines the disease course, but is influenced by several factors. This review assessed the factors that influence the uptake of PCa treatments in Nigeria, with a view to providing evidence for policies and other interventional approaches that enhance treatment uptake and PCa outcomes.

Methods

A review of relevant articles retrieved from electronic databases of Web of science, PubMed, Google scholar, African Journals online and Hinari was performed using relevant keywords. Relevant studies were also extracted from the bibliographic references of the identified studies. Peer-reviewed published articles that reported any associated factor to the uptake or utilisation of PCa treatment options from 2000 to 2023 were considered eligible, and the most pertinent reports were extracted and incorporated into this review.

Results

The uptake of PCa treatment options was observed to be dependent on several factors which could be grouped as economic, system-related and patient-related factors. Among these were the availability of treatment options and targeted therapies, cost and financial constraints, system-related barriers, funding gaps and lack of insurance coverage, patients’ beliefs and perceptions, access to radiotherapy services and access to PCa screening.

Conclusion

Several influencing factors posed barriers to the timely uptake of PCa treatment. Policies and strategies aimed at reducing or preventing these barriers are solicited from relevant stakeholders.

背景:前列腺癌(PCa)治疗的接受程度决定了疾病的进程,但也受到多种因素的影响。本综述评估了影响尼日利亚接受 PCa 治疗的因素,以期为提高治疗率和 PCa 治疗效果的政策和其他干预方法提供证据:使用相关关键词对从 Web of science、PubMed、Google scholar、African Journals online 和 Hinari 等电子数据库中检索到的相关文章进行了综述。还从已确定研究的参考文献中提取了相关研究。经同行评审发表的文章中,凡是报道了2000年至2023年期间PCa治疗方案的接受或使用情况的相关因素的,均被视为符合条件,最相关的报道被提取出来并纳入本综述:结果:据观察,PCa 治疗方案的采用取决于多个因素,可归纳为经济因素、系统相关因素和患者相关因素。这些因素包括治疗方案的可获得性、目标方案的可获得性、成本和经济限制、与系统相关的障碍、资金缺口和缺乏保险、患者的观念和看法、放射治疗服务的可获得性以及 PCa 筛查的可获得性:结论:一些影响因素对及时接受 PCa 治疗构成了障碍。请相关利益方制定旨在减少或预防这些障碍的政策和战略。
{"title":"A review of factors influencing the uptake of prostate cancer treatment in Nigeria","authors":"Chinonyerem O. Iheanacho ,&nbsp;Valentine U. Odili","doi":"10.1016/j.jcpo.2024.100487","DOIUrl":"10.1016/j.jcpo.2024.100487","url":null,"abstract":"<div><h3>Background</h3><p>The uptake of prostate cancer (PCa) treatment determines the disease course, but is influenced by several factors. This review assessed the factors that influence the uptake of PCa treatments in Nigeria, with a view to providing evidence for policies and other interventional approaches that enhance treatment uptake and PCa outcomes.</p></div><div><h3>Methods</h3><p>A review of relevant articles retrieved from electronic databases of Web of science, PubMed, Google scholar, African Journals online and Hinari was performed using relevant keywords. Relevant studies were also extracted from the bibliographic references of the identified studies. Peer-reviewed published articles that reported any associated factor to the uptake or utilisation of PCa treatment options from 2000 to 2023 were considered eligible, and the most pertinent reports were extracted and incorporated into this review.</p></div><div><h3>Results</h3><p>The uptake of PCa treatment options was observed to be dependent on several factors which could be grouped as economic, system-related and patient-related factors. Among these were the availability of treatment options and targeted therapies, cost and financial constraints, system-related barriers, funding gaps and lack of insurance coverage, patients’ beliefs and perceptions, access to radiotherapy services and access to PCa screening.</p></div><div><h3>Conclusion</h3><p>Several influencing factors posed barriers to the timely uptake of PCa treatment. Policies and strategies aimed at reducing or preventing these barriers are solicited from relevant stakeholders.</p></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141293810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cancer research funding in South Asia 南亚的癌症研究资金
IF 1.3 Q3 Medicine Pub Date : 2024-06-06 DOI: 10.1016/j.jcpo.2024.100489
Sehar Salim Virani , Kaleem Sohail Ahmed , Taylor Jaraczewski , Syed Nabeel Zafar

Background

The rising burden of cancer significantly influences the global economy and healthcare systems. While local and contextual cancer research is crucial, it is often limited by the availability of funds. In South Asia, with 1.7 million new cancer cases and 1.1 million deaths due to cancer in 2020, understanding cancer research funding trends is pivotal.

Methods

We reviewed funded cancer studies conducted between January 1, 2003, and Dec 31, 2022, using ClinicalTrials.gov, International Cancer Research Partnership (ICRP) Database, NIH World RePORT, and WHO International Clinical Trials Registry Platform (ICTRP). We included funded studies related to all cancer types, conducted in South Asian countries, namely Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, and Sri Lanka.

Results

We identified 6561 funded cancer studies from South Asia between 2003 and 2022, increasing from 400 studies in 2003‐2007 to 3909 studies in 2018–2022. India had the highest number of funded cancer studies, while Afghanistan, Bhutan, and the Maldives had minimal or no funded cancer research output. Interventional studies (67.3%) were the most common study type funded. The most common cancer sites funded were breast (17.8%), lung (9.9%), oropharyngeal (6.2%), and cervical (5.0%) cancers. On the WHO ICTRP, international funding agencies contributed to a majority of studies (57.5%), except in India where local funding agencies (58.2%) funded more studies.

Conclusion

This study identified gaps in research funding distribution across cancer types and geographic areas in South Asia. This data can be used to optimize the distribution of cancer research funding in South Asia, fostering equitable advancement in cancer research.

背景日益沉重的癌症负担严重影响着全球经济和医疗保健系统。尽管因地制宜的癌症研究至关重要,但却往往受到资金供应的限制。我们利用 ClinicalTrials.gov、国际癌症研究合作组织 (ICRP) 数据库、美国国立卫生研究院世界报告 (NIH World RePORT) 和世界卫生组织国际临床试验登记平台 (ICTRP) 对 2003 年 1 月 1 日至 2022 年 12 月 31 日期间开展的受资助癌症研究进行了审查。我们纳入了在南亚国家(即阿富汗、孟加拉国、不丹、印度、马尔代夫、尼泊尔、巴基斯坦和斯里兰卡)开展的与所有癌症类型相关的受资助研究。结果我们发现,2003 年至 2022 年间,南亚有 6561 项癌症研究获得资助,从 2003-2007 年的 400 项增加到 2018-2022 年的 3909 项。印度获得资助的癌症研究数量最多,而阿富汗、不丹和马尔代夫获得资助的癌症研究成果极少或没有。介入性研究(67.3%)是最常见的资助研究类型。获得资助最多的癌症部位是乳腺癌(17.8%)、肺癌(9.9%)、口咽癌(6.2%)和宫颈癌(5.0%)。在世界卫生组织国际癌症研究项目中,国际资助机构资助了大多数研究(57.5%),但印度除外,当地资助机构(58.2%)资助了更多的研究。这些数据可用于优化南亚癌症研究资金的分配,促进癌症研究的公平发展。
{"title":"Cancer research funding in South Asia","authors":"Sehar Salim Virani ,&nbsp;Kaleem Sohail Ahmed ,&nbsp;Taylor Jaraczewski ,&nbsp;Syed Nabeel Zafar","doi":"10.1016/j.jcpo.2024.100489","DOIUrl":"https://doi.org/10.1016/j.jcpo.2024.100489","url":null,"abstract":"<div><h3>Background</h3><p>The rising burden of cancer significantly influences the global economy and healthcare systems. While local and contextual cancer research is crucial, it is often limited by the availability of funds. In South Asia, with 1.7 million new cancer cases and 1.1 million deaths due to cancer in 2020, understanding cancer research funding trends is pivotal.</p></div><div><h3>Methods</h3><p>We reviewed funded cancer studies conducted between January 1, 2003, and Dec 31, 2022, using ClinicalTrials.gov, International Cancer Research Partnership (ICRP) Database, NIH World RePORT, and WHO International Clinical Trials Registry Platform (ICTRP). We included funded studies related to all cancer types, conducted in South Asian countries, namely Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, and Sri Lanka.</p></div><div><h3>Results</h3><p>We identified 6561 funded cancer studies from South Asia between 2003 and 2022, increasing from 400 studies in 2003‐2007 to 3909 studies in 2018–2022. India had the highest number of funded cancer studies, while Afghanistan, Bhutan, and the Maldives had minimal or no funded cancer research output. Interventional studies (67.3%) were the most common study type funded. The most common cancer sites funded were breast (17.8%), lung (9.9%), oropharyngeal (6.2%), and cervical (5.0%) cancers. On the WHO ICTRP, international funding agencies contributed to a majority of studies (57.5%), except in India where local funding agencies (58.2%) funded more studies.</p></div><div><h3>Conclusion</h3><p>This study identified gaps in research funding distribution across cancer types and geographic areas in South Asia. This data can be used to optimize the distribution of cancer research funding in South Asia, fostering equitable advancement in cancer research.</p></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141289842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Implementation of a nationwide population-level cancer screening in Bhutan: A programmatic experience 在不丹实施全国范围的人口癌症筛查:项目经验。
IF 1.3 Q3 Medicine Pub Date : 2024-06-06 DOI: 10.1016/j.jcpo.2024.100488
Pempa , Thinley Dorji , Ugyen Tashi , Jamyang Choden , Choney Dema , Tandin Dorji

This article delves into Bhutan’s adept execution of a nationwide cancer screening initiative within the Health Flagship Programme, concentrating on gastric, cervical, and breast cancers. Despite challenges like the COVID-19 pandemic, infrastructure constraints, logistical complexities, health human resource shortages, and data management issues, the programme succeeded. The procurement and logistics management ensured the timely provision of essential medical equipment and test kits. Robust political commitment, a comprehensive advocacy programme, and community engagement were pivotal for the programme’s success. Impressive screening coverage for all three cancers showcased the transformative impact on cancer care, integrating technology and fostering community involvement. Recommendations highlight the need for strengthened integration, strategic approaches, and ongoing evaluation, positioning Bhutan's programme as a potential model for nations facing similar health challenges.

本文深入探讨了不丹在健康旗舰计划范围内实施的全国癌症筛查计划,该计划主要针对胃癌、宫颈癌和乳腺癌。尽管面临 COVID-19 大流行、基础设施限制、后勤复杂性、卫生人力资源短缺和数据管理问题等挑战,该计划仍然取得了成功。采购和物流管理确保了基本医疗设备和检测包的及时供应。坚定的政治承诺、全面的宣传计划和社区参与是该计划取得成功的关键。所有三种癌症的筛查覆盖率都令人印象深刻,显示了癌症护理、整合技术和促进社区参与的变革性影响。建议强调了加强整合、战略方法和持续评估的必要性,并将不丹的计划定位为面临类似健康挑战的国家的潜在典范。
{"title":"Implementation of a nationwide population-level cancer screening in Bhutan: A programmatic experience","authors":"Pempa ,&nbsp;Thinley Dorji ,&nbsp;Ugyen Tashi ,&nbsp;Jamyang Choden ,&nbsp;Choney Dema ,&nbsp;Tandin Dorji","doi":"10.1016/j.jcpo.2024.100488","DOIUrl":"10.1016/j.jcpo.2024.100488","url":null,"abstract":"<div><p>This article delves into Bhutan’s adept execution of a nationwide cancer screening initiative within the Health Flagship Programme, concentrating on gastric, cervical, and breast cancers. Despite challenges like the COVID-19 pandemic, infrastructure constraints, logistical complexities, health human resource shortages, and data management issues, the programme succeeded. The procurement and logistics management ensured the timely provision of essential medical equipment and test kits. Robust political commitment, a comprehensive advocacy programme, and community engagement were pivotal for the programme’s success. Impressive screening coverage for all three cancers showcased the transformative impact on cancer care, integrating technology and fostering community involvement. Recommendations highlight the need for strengthened integration, strategic approaches, and ongoing evaluation, positioning Bhutan's programme as a potential model for nations facing similar health challenges.</p></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141293811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The narrow road to expanded access 通往扩大开放的狭窄道路。
IF 1.3 Q3 Medicine Pub Date : 2024-06-05 DOI: 10.1016/j.jcpo.2024.100490
H.C. Post , T. Schutte , J. Voortman , I.H. Bartelink , H.W.M. van Laarhoven , M. Crul
{"title":"The narrow road to expanded access","authors":"H.C. Post ,&nbsp;T. Schutte ,&nbsp;J. Voortman ,&nbsp;I.H. Bartelink ,&nbsp;H.W.M. van Laarhoven ,&nbsp;M. Crul","doi":"10.1016/j.jcpo.2024.100490","DOIUrl":"10.1016/j.jcpo.2024.100490","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141288740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Global review of COVID-19 mitigation strategies and their impact on cancer service disruptions COVID-19 缓解战略及其对癌症服务中断影响的全球审查。
IF 1.3 Q3 Medicine Pub Date : 2024-06-01 DOI: 10.1016/j.jcpo.2024.100486
Richa Shah , Ching Ee Loo , Nader Mounir Hanna , Suzanne Hughes , Allini Mafra , Hanna Fink , Ethna McFerran , Montse Garcia , Suryakanta Acharya , Oliver Langselius , Clara Frick , Jean Niyigaba , Nwamaka Lasebikan , Julia Steinberg , Richard Sullivan , Freddie Bray , André Michel Ilbawi , Ophira Ginsburg , Karen Chiam , Jonathan Cylus , Isabelle Soerjomataram

During the COVID-19 pandemic, countries adopted mitigation strategies to reduce disruptions to cancer services. We reviewed their implementation across health system functions and their impact on cancer diagnosis and care during the pandemic. A systematic search was performed using terms related to cancer and COVID-19. Included studies reported on individuals with cancer or cancer care services, focusing on strategies/programs aimed to reduce delays and disruptions. Extracted data were grouped into four functions (governance, financing, service delivery, and resource generation) and sub-functions of the health system performance assessment framework. We included 30 studies from 16 countries involving 192,233 patients with cancer. Multiple mitigation approaches were implemented, predominantly affecting sub-functions of service delivery to control COVID-19 infection via the suspension of non-urgent cancer care, modified treatment guidelines, and increased telemedicine use in routine cancer care delivery. Resource generation was mainly ensured through adequate workforce supply. However, less emphasis on monitoring or assessing the effectiveness and financing of these strategies was observed. Seventeen studies suggested improved service uptake after mitigation implementation, yet the resulting impact on cancer diagnosis and care has not been established. This review emphasizes the importance of developing effective mitigation strategies across all health system (sub)functions to minimize cancer care service disruptions during crises. Deficiencies were observed in health service delivery (to ensure equity), governance (to monitor and evaluate the implementation of mitigation strategies), and financing. In the wake of future emergencies, implementation research studies that include pre-prepared protocols will be essential to assess mitigation impact across cancer care services.

在 COVID-19 大流行期间,各国采取了缓解策略以减少对癌症服务的干扰。我们回顾了这些策略在卫生系统各职能部门的实施情况及其对大流行期间癌症诊断和治疗的影响。我们使用与癌症和 COVID-19 相关的术语进行了系统性检索。纳入的研究报告涉及癌症患者或癌症护理服务,重点关注旨在减少延误和中断的策略/计划。提取的数据按照医疗系统绩效评估框架的四个功能(治理、融资、服务提供和资源生成)和子功能进行了分组。我们纳入了来自 16 个国家的 30 项研究,涉及 192,233 名癌症患者。通过暂停非紧急癌症治疗、修改治疗指南以及在常规癌症治疗中增加远程医疗的使用,实施了多种缓解方法,主要影响了提供服务的子功能,以控制 COVID-19 感染。主要通过提供充足的劳动力来确保资源的生成。然而,这些研究较少强调对这些战略的效果和资金的监测或评估。17 项研究表明,在实施缓解措施后,服务吸收率有所提高,但由此对癌症诊断和护理产生的影响尚未确定。本综述强调了在所有医疗系统(子)功能中制定有效的缓解战略以尽量减少危机期间癌症护理服务中断的重要性。在提供医疗服务(确保公平)、治理(监测和评估减灾战略的实施情况)和融资方面都存在不足。在未来的紧急情况发生后,包括预先准备的协议在内的实施研究对于评估缓解措施对癌症治疗服务的影响至关重要。
{"title":"Global review of COVID-19 mitigation strategies and their impact on cancer service disruptions","authors":"Richa Shah ,&nbsp;Ching Ee Loo ,&nbsp;Nader Mounir Hanna ,&nbsp;Suzanne Hughes ,&nbsp;Allini Mafra ,&nbsp;Hanna Fink ,&nbsp;Ethna McFerran ,&nbsp;Montse Garcia ,&nbsp;Suryakanta Acharya ,&nbsp;Oliver Langselius ,&nbsp;Clara Frick ,&nbsp;Jean Niyigaba ,&nbsp;Nwamaka Lasebikan ,&nbsp;Julia Steinberg ,&nbsp;Richard Sullivan ,&nbsp;Freddie Bray ,&nbsp;André Michel Ilbawi ,&nbsp;Ophira Ginsburg ,&nbsp;Karen Chiam ,&nbsp;Jonathan Cylus ,&nbsp;Isabelle Soerjomataram","doi":"10.1016/j.jcpo.2024.100486","DOIUrl":"10.1016/j.jcpo.2024.100486","url":null,"abstract":"<div><p>During the COVID-19 pandemic, countries adopted mitigation strategies to reduce disruptions to cancer services. We reviewed their implementation across health system functions and their impact on cancer diagnosis and care during the pandemic. A systematic search was performed using terms related to cancer and COVID-19. Included studies reported on individuals with cancer or cancer care services, focusing on strategies/programs aimed to reduce delays and disruptions. Extracted data were grouped into four functions (governance, financing, service delivery, and resource generation) and sub-functions of the health system performance assessment framework. We included 30 studies from 16 countries involving 192,233 patients with cancer. Multiple mitigation approaches were implemented, predominantly affecting sub-functions of service delivery to control COVID-19 infection via the suspension of non-urgent cancer care, modified treatment guidelines, and increased telemedicine use in routine cancer care delivery. Resource generation was mainly ensured through adequate workforce supply. However, less emphasis on monitoring or assessing the effectiveness and financing of these strategies was observed. Seventeen studies suggested improved service uptake after mitigation implementation, yet the resulting impact on cancer diagnosis and care has not been established. This review emphasizes the importance of developing effective mitigation strategies across all health system (sub)functions to minimize cancer care service disruptions during crises. Deficiencies were observed in health service delivery (to ensure equity), governance (to monitor and evaluate the implementation of mitigation strategies), and financing. In the wake of future emergencies, implementation research studies that include pre-prepared protocols will be essential to assess mitigation impact across cancer care services.</p></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141237887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiotherapy resources in the Philippines: A 2022 update 菲律宾的放射治疗资源:2022 年更新。
IF 1.3 Q3 Medicine Pub Date : 2024-05-18 DOI: 10.1016/j.jcpo.2024.100485
Johanna Patricia A. Canal , Michelle Ann B. Eala , Ma. Veronica Pia N. Arevalo , Edward Christopher Dee , Henri Cartier S. Co

Background

Cancer is the third leading cause of death in the Philippines. Radiotherapy (RT) is integral to the treatment and palliation of cancer. Therefore, RT resources across the country must be surveyed and optimized.

Methods

Online surveys were sent to the heads of all 50 RT facilities in the Philippines. The survey included items regarding the facility itself, personnel, and available services.

Findings

The survey had a 98% response rate. 76% of RT facilities in the Philippines are privately owned; 12 are government/public institutions and 8 are academic centers. Over a third are in the National Capital Region; three regions are without a single RT facility. For a population of >110 million, the Philippines has 53 linear accelerators, 125 radiation oncologists, 56 residents, 114 medical physicists, 113 radiation oncology nurses, and 343 radiation therapists. Nine radiation oncology residency programs are active. All facilities are capable of 3D conformal radiotherapy, and 96% are capable of intensity modulated radiotherapy. <30% offer stereotactic radiotherapy, and <50% offer HDR brachytherapy.

Conclusion

While there has been significant expansion of RT resources over the years, RT remains inaccessible for many in the Philippines. Urgent investment in training and retaining RT personnel is needed as well. Policy summary: With its current cancer burden, the Philippines needs at least 170 linear accelerators, 300 radiation oncologists, and 150 medical physicists. Public/government cancer centers must be built, with priority given to regions without RT facilities. HDR brachytherapy and stereotactic radiotherapy services must also be expanded. A national RT task force must be created to ensure the quality, availability, and accessibility of RT in the Philippines. Further work exploring payment schemes that improve access to RT and mitigate financial toxicity is needed, as well as integration of radiation oncology providers and health policy experts into national health system decision making.

背景:癌症是菲律宾人的第三大死因。放射治疗(RT)是治疗和缓解癌症不可或缺的手段。因此,必须对全国的 RT 资源进行调查和优化:向菲律宾所有 50 家放射治疗机构的负责人发送了在线调查问卷。调查内容包括设施本身、人员和可用服务等项目:调查的回复率为 98%。菲律宾 76% 的 RT 设施为私人所有;12 家为政府/公共机构,8 家为学术中心。超过三分之一的设施位于国家首都地区;有三个地区没有一家 RT 设施。菲律宾人口超过 1.1 亿,拥有 53 台直线加速器、125 名放射肿瘤学家、56 名住院医师、114 名医学物理学家、113 名放射肿瘤学护士和 343 名放射治疗师。目前有 9 个放射肿瘤住院医师培训项目。所有设施都能进行三维适形放射治疗,96% 的设施能进行调强放射治疗。结论:尽管多年来菲律宾的放射治疗资源得到了大幅扩充,但许多菲律宾人仍然无法获得放射治疗服务。此外,还需要在培训和留住 RT 人员方面进行紧急投资。政策摘要:以目前的癌症负担,菲律宾至少需要 170 台直线加速器、300 名放射肿瘤学家和 150 名医学物理学家。必须建立公共/政府癌症中心,优先考虑没有 RT 设施的地区。还必须扩大 HDR 近距离放射治疗和立体定向放射治疗服务。必须成立国家 RT 工作组,以确保菲律宾 RT 的质量、可用性和可及性。还需要进一步开展工作,探索可改善 RT 可及性和减轻经济毒性的支付方案,并将放射肿瘤服务提供者和卫生政策专家纳入国家卫生系统的决策中。
{"title":"Radiotherapy resources in the Philippines: A 2022 update","authors":"Johanna Patricia A. Canal ,&nbsp;Michelle Ann B. Eala ,&nbsp;Ma. Veronica Pia N. Arevalo ,&nbsp;Edward Christopher Dee ,&nbsp;Henri Cartier S. Co","doi":"10.1016/j.jcpo.2024.100485","DOIUrl":"10.1016/j.jcpo.2024.100485","url":null,"abstract":"<div><h3>Background</h3><p>Cancer is the third leading cause of death in the Philippines. Radiotherapy (RT) is integral to the treatment and palliation of cancer. Therefore, RT resources across the country must be surveyed and optimized.</p></div><div><h3>Methods</h3><p>Online surveys were sent to the heads of all 50 RT facilities in the Philippines. The survey included items regarding the facility itself, personnel, and available services.</p></div><div><h3>Findings</h3><p>The survey had a 98% response rate. 76% of RT facilities in the Philippines are privately owned; 12 are government/public institutions and 8 are academic centers. Over a third are in the National Capital Region; three regions are without a single RT facility. For a population of &gt;110 million, the Philippines has 53 linear accelerators, 125 radiation oncologists, 56 residents, 114 medical physicists, 113 radiation oncology nurses, and 343 radiation therapists. Nine radiation oncology residency programs are active. All facilities are capable of 3D conformal radiotherapy, and 96% are capable of intensity modulated radiotherapy. &lt;30% offer stereotactic radiotherapy, and &lt;50% offer HDR brachytherapy.</p></div><div><h3>Conclusion</h3><p>While there has been significant expansion of RT resources over the years, RT remains inaccessible for many in the Philippines. Urgent investment in training and retaining RT personnel is needed as well. Policy summary: With its current cancer burden, the Philippines needs at least 170 linear accelerators, 300 radiation oncologists, and 150 medical physicists. Public/government cancer centers must be built, with priority given to regions without RT facilities. HDR brachytherapy and stereotactic radiotherapy services must also be expanded. A national RT task force must be created to ensure the quality, availability, and accessibility of RT in the Philippines. Further work exploring payment schemes that improve access to RT and mitigate financial toxicity is needed, as well as integration of radiation oncology providers and health policy experts into national health system decision making.</p></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2024-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141072046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Authorship characteristics of hematology and oncology education chapters: A comprehensive analysis 血液学与肿瘤学教育章节的作者特点:综合分析。
IF 1.3 Q3 Medicine Pub Date : 2024-05-13 DOI: 10.1016/j.jcpo.2024.100484
Heba Altarawneh , Mohammad Manasrah , Yasemin Al Shanableh , Arwa Saed Aldien , Mohannad A. Manasrah , Safah Khan , Lina Altarawneh , Leen Mohammad Al-Kraimeen , Farah Al Kasaji , Asalah Alareeki , Samer Al Hadidi

Introduction

Achieving diversity and equity in healthcare, especially within academic and clinical spheres, poses significant challenges. This study aims to evaluate gender representation, geographical diversity among authors, and disclosure of conflicts of interest (COIs) in educational materials published by the American Society of Clinical Oncology (ASCO) and the American Society of Hematology (ASH).

Materials and methods

We conducted a comprehensive cross-sectional analysis covering all volumes of ASCO and ASH educational chapters from 2012 to 2022 and 2000 to 2022, respectively. Author data were extracted from the official websites of ASCO and ASH educational books, focusing on names, affiliations, countries of practice, COIs, and publication titles/subjects.

Results

Analysis of 2796 articles revealed significant trends in gender representation. Women comprised 44 % of first authors and 38 % of last authors in ASCO educational books, and 39 % of first authors and 39% of last authors in ASH educational books. Notably, there was a marked increase in female first and last authors over time across both ASCO and ASH publications (p < 0.001). Geographical diversity showed disparities, with the majority of authors affiliated with US institutions (72 % of first and last authors). International authors were less represented, with Canada, the UK, and Italy prominent among articles featuring international women authors. A substantial portion of analyzed articles disclosed COIs, mainly research funding, honoraria, and travel expenses.

Discussion

Our findings suggest a notable rise in female authorship, potentially reflecting efforts by ASH and ASCO to promote diversity. International authorship remained stable, while COIs were prevalent, primarily involving research funding. Addressing the need for greater international engagement and improving COI reporting quality are crucial to promote inclusivity and transparency in academic publications.

导言:在医疗保健领域,尤其是在学术和临床领域,实现多样性和公平性是一项重大挑战。本研究旨在评估美国临床肿瘤学会(ASCO)和美国血液学会(ASH)出版的教育材料中作者的性别代表性、地域多样性以及利益冲突(COIs)披露情况:我们分别对 2012 年至 2022 年和 2000 年至 2022 年的所有 ASCO 和 ASH 教育章节进行了全面的横向分析。我们从ASCO和ASH教育书籍的官方网站上提取了作者数据,重点关注作者姓名、所属单位、执业国家、COIs和出版物标题/主题:对 2,796 篇文章进行分析后发现,性别代表性呈现出显著趋势。在 ASCO 教育书籍中,女性占第一作者的 44%,占最后作者的 38%;在 ASH 教育书籍中,女性占第一作者的 39%,占最后作者的 39%。值得注意的是,随着时间的推移,ASCO 和 ASH 出版物中的女性第一作者和最后作者都有明显增加(p < 0.001)。地域多样性显示出差异,大多数作者隶属于美国机构(占第一作者和最后作者的 72%)。国际作者的比例较低,加拿大、英国和意大利在国际女性作者的文章中占有突出地位。相当一部分分析文章披露了COIs,主要是研究经费、酬金和差旅费:我们的研究结果表明,女性作者人数明显增加,这可能反映了ASH和ASCO为促进多样性所做的努力。国际作者人数保持稳定,而COIs普遍存在,主要涉及研究经费。要促进学术出版物的包容性和透明度,就必须满足更多国际参与的需求并提高COI报告的质量。
{"title":"Authorship characteristics of hematology and oncology education chapters: A comprehensive analysis","authors":"Heba Altarawneh ,&nbsp;Mohammad Manasrah ,&nbsp;Yasemin Al Shanableh ,&nbsp;Arwa Saed Aldien ,&nbsp;Mohannad A. Manasrah ,&nbsp;Safah Khan ,&nbsp;Lina Altarawneh ,&nbsp;Leen Mohammad Al-Kraimeen ,&nbsp;Farah Al Kasaji ,&nbsp;Asalah Alareeki ,&nbsp;Samer Al Hadidi","doi":"10.1016/j.jcpo.2024.100484","DOIUrl":"10.1016/j.jcpo.2024.100484","url":null,"abstract":"<div><h3>Introduction</h3><p>Achieving diversity and equity in healthcare, especially within academic and clinical spheres, poses significant challenges. This study aims to evaluate gender representation, geographical diversity among authors, and disclosure of conflicts of interest (COIs) in educational materials published by the American Society of Clinical Oncology (ASCO) and the American Society of Hematology (ASH).</p></div><div><h3>Materials and methods</h3><p>We conducted a comprehensive cross-sectional analysis covering all volumes of ASCO and ASH educational chapters from 2012 to 2022 and 2000 to 2022, respectively. Author data were extracted from the official websites of ASCO and ASH educational books, focusing on names, affiliations, countries of practice, COIs, and publication titles/subjects.</p></div><div><h3>Results</h3><p>Analysis of 2796 articles revealed significant trends in gender representation. Women comprised 44 % of first authors and 38 % of last authors in ASCO educational books, and 39 % of first authors and 39% of last authors in ASH educational books. Notably, there was a marked increase in female first and last authors over time across both ASCO and ASH publications (p &lt; 0.001). Geographical diversity showed disparities, with the majority of authors affiliated with US institutions (72 % of first and last authors). International authors were less represented, with Canada, the UK, and Italy prominent among articles featuring international women authors. A substantial portion of analyzed articles disclosed COIs, mainly research funding, honoraria, and travel expenses.</p></div><div><h3>Discussion</h3><p>Our findings suggest a notable rise in female authorship, potentially reflecting efforts by ASH and ASCO to promote diversity. International authorship remained stable, while COIs were prevalent, primarily involving research funding. Addressing the need for greater international engagement and improving COI reporting quality are crucial to promote inclusivity and transparency in academic publications.</p></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2024-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140943781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to “The use of the biosimilar drug can lead to large health care savings that can be reinvested for continued innovation: Analysis of consumption of an Italian health care company” [J. Cancer Pol. 40 (2024) 100473] 对 "使用生物仿制药可节省大量医疗费用,这些费用可再投资于持续创新:一家意大利医疗保健公司的消费分析" [J. Cancer Pol. 40 (2024) 100473] 的更正
IF 2 Q3 HEALTH POLICY & SERVICES Pub Date : 2024-05-03 DOI: 10.1016/j.jcpo.2024.100479
{"title":"Corrigendum to “The use of the biosimilar drug can lead to large health care savings that can be reinvested for continued innovation: Analysis of consumption of an Italian health care company” [J. Cancer Pol. 40 (2024) 100473]","authors":"","doi":"10.1016/j.jcpo.2024.100479","DOIUrl":"10.1016/j.jcpo.2024.100479","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213538324000134/pdfft?md5=48244abdc80016cda2c858510cb39ebb&pid=1-s2.0-S2213538324000134-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142076968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sugar tax in Poland – Bittersweet lessons three years after implementation 波兰的糖税--实施三年后苦乐参半的教训。
IF 1.3 Q3 Medicine Pub Date : 2024-04-29 DOI: 10.1016/j.jcpo.2024.100483
Paweł Koczkodaj , Irmina Maria Michalek
{"title":"Sugar tax in Poland – Bittersweet lessons three years after implementation","authors":"Paweł Koczkodaj ,&nbsp;Irmina Maria Michalek","doi":"10.1016/j.jcpo.2024.100483","DOIUrl":"10.1016/j.jcpo.2024.100483","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140863531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Cancer Policy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1